Capitainer AB has appointed a new Board of Directors as the company accelerates its international expansion and scales up to meet growing global demand. With deep and diverse expertise spanning diagnostics, healthtech, commercialization, and leadership, the new board reflects Capitainer’s strategic shift from a high-potential innovator to a globally positioned growth company.
The updated board marks a decisive step to support Capitainer’s ambition to lead the microsampling revolution. Several new members are joining, bringing critical capabilities to guide the company’s scale-up across markets and applications. Louise Warme remains from the previous board, providing valuable continuity.
“As Capitainer continues to grow and expand into new markets, this new Board brings world-class expertise and insight that will be instrumental as we advance our technology, scale our operations, and deliver impact on a global level. I look forward to work with this amazing group of people” says Christopher Aulin, CEO of Capitainer.
Capitainer is pleased to introduce several of the newly appointed members of its Board of Directors:
Richard Tejme – Chairman
Seasoned investor, advisor, and board director with over 25 years of executive experience as CFO and CEO across multiple industries.
Currently Board Member at Mindler, Chairman of Copture and advisor to Myrspoven.
Richard brings strong financial acumen, strategic leadership, and deep experience in scaling and governing innovative growth-stage companies.
Alain Pluquet – Board Member
Former Corporate Vice President and CTO at bioMérieux, where he led Innovation, R&D and Data Analytics strategy. Advisor to the Mérieux investment arms.
Holds a PhD in particle physics from Pierre et Marie Curie University.
Alain offers deep expertise in innovation strategy, clinical product development, and international healthtech commercialization.
Thomas Lindahl – Board Member
Global Chief Medical Officer at Unilabs, responsible for clinical strategy, governance and professional education across international diagnostic operations.
Medical doctor and specialist in radiology, with a PhD in oncology from Karolinska Institutet.
Thomas has played a central role in expanding Unilabs’ clinical network and in standardizing clinical practices across the group, bringing Capitainer strategic medical insight and leadership from one of Europe’s largest diagnostics providers.
Louise Warme – Board Member
Head of We Venture Capital, the diagnostics-focused corporate venture arm of Werfen.
Medical doctor, researcher and Clinical Innovations Fellow at KTH and Karolinska Institutet.
Has over 10 years of experience in life science investing and >18 board roles; previously founding CEO of a medtech startup.
She currently serves on the board of Axithra and as an observer for Deepull and Zetta Genomics. Louise brings deep expertise in diagnostics investing and growth strategy, healthtech entrepreneurship, and venture capital.
For more information, please contact:
Christopher Aulin, CEO
Phone: +46 (0)708 977577
Email: christopher.aulin@capitainer.com
About Capitainer
Capitainer AB is a Swedish MedTech company that develops and sells patient-centric solutions for self-sampling of blood, plasma, and urine. Founded in 2016, Capitainer has developed unique technologies for collecting and drying exact volumes of fluid within easy-to-use sampling cards. These cards may be sent as standard post to relevant testing laboratories, thus bypassing the need for cold chain logistics and specialised packaging. Capitainer’s products are market-leading with respect to precision and accuracy, with demonstrated equal performance to established pipetting methods. The products are applicable within several market segments, including but not limited to, clinical biomarkers, therapeutic drug monitoring, genomics, drug abuse and doping testing, and R&D and clinical studies.